Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Hua Medicine's share price for the quarter that ended in Dec. 2023 was HK$1.97. Hua Medicine's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 980.52 Mil. Therefore, Hua Medicine's market cap for the quarter that ended in Dec. 2023 was HK$1,931.63 Mil.
Hua Medicine's quarterly market cap
declined
from Dec. 2022 (HK$3,628.22 Mil) to Jun. 2023 (HK$1,614.89 Mil) but then
increased
from Jun. 2023 (HK$1,614.89 Mil) to Dec. 2023 (HK$1,931.63 Mil).
Hua Medicine's annual market cap
declined
from Dec. 2021 (HK$3,651.85 Mil) to Dec. 2022 (HK$3,628.22 Mil) and
declined
from Dec. 2022 (HK$3,628.22 Mil) to Dec. 2023 (HK$1,931.63 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hua Medicine's Enterprise Value for Today is HK$181.84 Mil.
Hua Medicine Market Cap Historical Data
The historical data trend for Hua Medicine's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hua Medicine's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Market Cap distribution charts can be found below:
* The bar in red indicates where Hua Medicine's Market Cap falls into.
Hua Medicine Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Hua Medicine's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HKSE:02552) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hua Medicine Market Cap Related Terms
Thank you for viewing the detailed overview of Hua Medicine's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Hua Medicine is an investment holding company. It is engaged in development and commercialization of a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC. Some of its products are Dorzagliatin + Metformin, Dorzagliatin, Dorzagliatin + Pioglitazone and mGLUR5 NAM, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02552 has been successfully added to your 